Allergan Board Rejects Valeant Takeover Offer

Mon, 05/12/2014 - 10:04am

IRVINE, Calif. (AP) -- Botox maker Allergan is rejecting a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited $46 billion offer undervalues the company and carries significant risk.

Shortly after Canada's Valeant and activist investor Bill Ackman made their offer public last month, Valeant announced a so-called poison pill plan, a defensive tactic that makes a buyout prohibitively expensive.

Valeant and Ackman offered to exchange each Allergan share for $48.30 in cash and a portion of shares of Valeant Pharmaceuticals International Inc.

Allergan stockholders would own 43 percent of the combined company under that proposal. Allergan Inc. says Valeant's uncertain long-term growth prospects and business model create a risk for Allergan shareholders.

Allergan Inc., based in Irvine, has long been considered one of the star performers in the specialty pharmaceutical sector.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.